n-3 fatty acids have a well known effect on hypertriglyceridemia in humans. The effect is a dramatic decrease in plasma triglycerides in hypertriglyceridemic patients treated with a weekly dose of 3,6g of n-3 fatty acids. I would like to know the mechanism of this effect on VLDL, as a precursor of the Intermediate density lipoproteins structure. And the oxidability of both lipoproteins,the post treatment - VLDL depleted of triglycerides, and its remnant Intermediate density lipoproteins.
Many European studies differ completely with outcomes compared to USA studies. In essence, the difference of source creates the issue.
Most USA studies are more often survey or supplement studies, while most EU studies are whole food studies.
Most USA information portals, like this one: http://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/expert-answers/vldl-cholesterol/faq-20058275
are slanted towards pharmaceutical agenda rather than actual human cell biology.
VLDL and like triglycerides, are more often utilized as conversion compounds in hormonal synthesis pathways along the ergocalciferal path.
So without knowing what your end target of the research; it is hard to just finalize "a" oxidation or reduction pathway when there are a few.